Viatris Inc(VTRS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:01 AM ET (Korea 9/11 17:01)
Full metrics table
| Index | S&P 500 | P/E | - | EPS (ttm) | -0.36 | Insider Own | 2.02% | Shs Outstand | 1.16B | Perf Week | -4.15% |
| Market Cap | 18.81B | Forward P/E | 6.14 | EPS next Y | 6.17% | Insider Trans | -0.3% | Shs Float | 1.13B | Perf Month | 0.61% |
| Enterprise Value | 31.03B | PEG | 0.89 | EPS next Q | 0.65 | Inst Own | 92.08% | Short Float | 3.29% | Perf Quarter | 3.87% |
| Income | -0.41B | P/S | 1.28 | EPS this Y | 6.85% | Inst Trans | 4.47% | Short Ratio | 3.88 | Perf Half Y | 17.25% |
| Sales | 14.75B | P/B | 1.33 | EPS next 5Y | 6.88% | ROA | -1.12% | Short Interest | 37.02M | Perf YTD | 31.57% |
| Book/sh | 12.34 | P/C | 13.35 | EPS past 3/5Y | - -21.93% | ROE | -2.75% | 52W High | -10.93% ($18.39) | Perf Year | 59.96% |
| Cash/sh | 1.23 | P/FCF | 9.62 | Sales past 3/5Y | -4.04% 3.66% | ROIC | -1.58% | 52W Low | 73.79% ($9.43) | Perf 3Y | 62.02% |
| Dividend Est. | $0.52 (3.16%) | EV/EBITDA | 7.33 | EPS Y/Y TTM | 87.81% | Gross Margin | 39.58% | Volatility(W/M) | 2.39% 2.4% | Perf 5Y | 18.7% |
| Dividend TTM | 0.48 | EV/Sales | 2.1 | Sales Y/Y TTM | 4.92% | Oper. Margin | 9.69% | ATR (14) | 0.45 | Perf 10Y | -58.94% |
| Dividend Ex-Date | 2026/8/21 | Quick Ratio | 0.87 | EPS Q/Q | -2517.95% | Profit Margin | -2.78% | RSI (14) | 44.75 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.49 | Sales Q/Q | 5.05% | SMA20 | -0.8% ($16.51) | Beta | 0.87 | Target Price | $18.88 |
| Payout | - | Debt/Eq | 0.96 | Earnings | 2026/8/6 | SMA50 | -2.41% ($16.78) | Rel Volume | 0.94 | Prev Close | $16.5 |
| Employees | 30000 | LT Debt/Eq | 0.83 | EPS/Sales Surpr. | 14.79% 2.21% | SMA200 | 10.58% ($14.81) | Avg Volume(3M) | 9.55M | Price | $16.38 |
| IPO | 1980/3/17 | Option/Short | Yes/Yes | Trades | 36813 | Volume | 9,005,878 | Change | -0.73% |
Company
VTRS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 A pharmaceutical company that supplies generics (copy drugs) and specialty pharmaceuticals globally. It holds a broad portfolio of generics, biosimilars, and branded drugs across various therapeutic areas, supplying medicines to markets around the world. It is one of the leading generic and specialty pharmaceutical companies with an extensive product portfolio and global distribution network.
Over the past 1 year, on the higher side
11% below its 1-year high.
VTRS has weak earning power
9.69% of revenue is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +6.8% this year.
Tap to view numbers
The stock looks undervalued
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +62.0% if bought 5 years ago.
Tap to view numbers
Dividends are paid consistently
Pays 3.16% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 92.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
DUSA 0.05%
IHE 0.04%
ADPV 0.04%
DWLD 0.04%
LBAY 0.04%It ranks #4 in the industry
Based on market cap of $19B.
VTRS $19B PER -
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is VTRS?
VTRS belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of VTRS?
The market cap of VTRS is approximately $18.8B, ranking 624 within its sector.
Does VTRS pay dividends?
VTRS has a dividend yield of approximately 3.16%, with an annual dividend of $0.52.
What is the 52-week high and low for VTRS?
VTRS has recorded a 52-week high of $18.39 and a low of $9.43.
